Placebo orodispersible tablet twice daily

DRUG2 trials

Sponsors

Dr. Falk Pharma GmbH

Conditions

Eosinophilic Esophagitis

Phase 3

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

CompletedNCT02434029

Dr. Falk Pharma GmbHEosinophilic Esophagitis

Start: 2015-11-11End: 2016-10-04Updated: 2017-02-03

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

CompletedNCT02493335

Dr. Falk Pharma GmbHEosinophilic Esophagitis

Start: 2016-01-15End: 2020-12-11Updated: 2021-10-07

Related Papers

Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study

Clinical Gastroenterology and Hepatology2024-12-1610 citations

O38 1mg once daily orodispersible budesonide can maintain clinical remission in adults with eosinophilic oesophagitis

Oral Presentations2023-06-01

Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.

2020-07-25133 citations

Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.

2019-03-26200 citations